Arsenio Vargas-Vázquez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arsenio Vargas-Vázquez has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Omar Yaxmehen Bello-Chavolla
Instituto Nacional de Geriatría, Mexico City, Mexico
43 shared publications - Neftali Eduardo Antonio-Villa
Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez , Mexico City
32 shared publications - Carlos Alberto Fermín-Martínez
Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico
23 shared publications - Carlos Alberto Aguilar Salinas
Dirección de Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Ciudad de México, México...
19 shared publications - Luisa Fernández-Chirino
Research Division, Instituto Nacional de Geriatría
16 shared publications - Daniel Ramírez-García
Research Division, Instituto Nacional de Geriatría
12 shared publications
Latest Publications
- 1 July 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (7)
Evolving Patterns of Prevalence and Management of Hypertension Phenotypes in Mexico: A 2-Decade Analysis of Nationally Representative Surveys
BACKGROUND: Systemic arterial hypertension is a public health concern, and timely diagnosis and management are critical to mitigate long-term effects. Here, we evaluated prevalence trends and determinants of hypertension phenotypes in the Mexican population over 2 decades. METHODS: We analyzed cross-sectional Mexican Health and Nutrition Surveys (2000–2024), including 146 904 adults aged ≥20 years. Hypertension was defined as self-reported diagnosis or blood pressure ≥140/90 mm Hg; undiagnosed hypertension (UDH) as blood pressure ≥140/90 mm Hg without prior diagnosis; and untreated hypertension as a prior diagnosis without treatment. UDH was classified as isolated systolic, isolated diastolic, or systolic-diastolic hypertension. We assessed trends with Poisson models and determinants of UDH and untreated hypertension with logistic models. RESULTS: We observed an overall decrease in hypertension prevalence from 33.1% in 2000 to 26.0% in 2024, concurrently with increases in diagnosed (12.3%–19.3%) and decreases in undiagnosed (20.7%–6.7%) hypertension. Isolated diastolic hypertension and systolic-diastolic hypertension declined over time, while isolated systolic hypertension increased, particularly among older adults. Among diagnosed cases, treatment percentage increased (69%–80%) and blood pressure control improved (40.5%–81.1%). Despite these trends, by 2024, ≈5 million Mexican adults still had UDH (25.9% of all hypertension cases), 2.9 million remained untreated, and 2.7 million were uncontrolled. Lack of diagnosis and treatment were more likely among men, individuals with unhealthy lifestyles, and those with social disadvantage. CONCLUSIONS: Results highlight evolving trends in hypertension diagnosis, treatment, and control in Mexico, with persistent challenges in UDH and untreated hypertension. Strengthening screening, treatment access, and equity is crucial to reduce hypertension-related cardiovascular risk.
- 1 July 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (7)
Evolving Patterns of Prevalence and Management of Hypertension Phenotypes in Mexico: A 2-Decade Analysis of Nationally Representative Surveys
BACKGROUND: Systemic arterial hypertension is a public health concern, and timely diagnosis and management are critical to mitigate long-term effects. Here, we evaluated prevalence trends and determinants of hypertension phenotypes in the Mexican population over 2 decades. METHODS: We analyzed cross-sectional Mexican Health and Nutrition Surveys (2000–2024), including 146 904 adults aged ≥20 years. Hypertension was defined as self-reported diagnosis or blood pressure ≥140/90 mm Hg; undiagnosed hypertension (UDH) as blood pressure ≥140/90 mm Hg without prior diagnosis; and untreated hypertension as a prior diagnosis without treatment. UDH was classified as isolated systolic, isolated diastolic, or systolic-diastolic hypertension. We assessed trends with Poisson models and determinants of UDH and untreated hypertension with logistic models. RESULTS: We observed an overall decrease in hypertension prevalence from 33.1% in 2000 to 26.0% in 2024, concurrently with increases in diagnosed (12.3%–19.3%) and decreases in undiagnosed (20.7%–6.7%) hypertension. Isolated diastolic hypertension and systolic-diastolic hypertension declined over time, while isolated systolic hypertension increased, particularly among older adults. Among diagnosed cases, treatment percentage increased (69%–80%) and blood pressure control improved (40.5%–81.1%). Despite these trends, by 2024, ≈5 million Mexican adults still had UDH (25.9% of all hypertension cases), 2.9 million remained untreated, and 2.7 million were uncontrolled. Lack of diagnosis and treatment were more likely among men, individuals with unhealthy lifestyles, and those with social disadvantage. CONCLUSIONS: Results highlight evolving trends in hypertension diagnosis, treatment, and control in Mexico, with persistent challenges in UDH and untreated hypertension. Strengthening screening, treatment access, and equity is crucial to reduce hypertension-related cardiovascular risk.
- Open Access
- 3 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e044366
Cardiovascular Risk Management in Adults With Diagnosed Diabetes in Mexico From 2016 to 2023: A Retrospective Analysis of Nationally Representative Surveys
Background: Effective cardiovascular disease (CVD) risk management is essential for optimal diabetes care. Here, we estimated the prevalence and determinants of CVD risk factor control among individuals with diagnosed diabetes in Mexico. Methods: We analyzed data from individuals ≥20 years with diagnosed diabetes from 2016 to 2023 Mexican National Health and Nutrition Surveys. We estimated the prevalence of glycemic, blood pressure, noncurrent smoking, low‐density lipoprotein cholesterol, and combined CVD risk factor control. We estimated use of blood pressure‐lowering, cholesterol‐lowering, and glucose‐lowering medication and explored determinants of control achievement using logistic regression. Results: We analyzed data from 2916 participants, representing 43.2 million adults with diagnosed diabetes during 2016 to 2023. In 2023, glycemic control was 29% (95% CI, 21%–38%), blood pressure control 22.9% (95% CI, 14%–31%), and noncurrent smoking 89% (95% CI, 81%–96%). The prevalence of high or very‐high CVD risk using Systematic Coronary Risk Evaluation 2‐Diabetes increased from 59.8% (95% CI, 52.1%–67.0%) in 2016 to 68.4% (95% CI, 55.6%–78.9%) in 2023, representing ~5.1 million adults. Low‐density lipoprotein cholesterol control increased from 2.8% (95% CI, 1.2%–4.4%) in 2016 to 6.6% (95% CI, 1.9%–11.2%) in 2023 and statin use from 5.5% in 2016 to 63% in 2023. Combined risk factor control achievement was low due to suboptimal low‐density lipoprotein cholesterol control and was more likely achieved in women, younger individuals, and those with college education or living in states with higher socioeconomic position. Conclusions: Despite increasing CVD risk during this period, glycemic and CVD risk factor management for adults with diabetes in Mexico remains suboptimal. Our findings suggest a need for strategies to improve CVD risk management to reduce diabetes‐related mortality and complications.
- 3 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e044366
Open AccessCardiovascular Risk Management in Adults With Diagnosed Diabetes in Mexico From 2016 to 2023: A Retrospective Analysis of Nationally Representative Surveys
Background: Effective cardiovascular disease (CVD) risk management is essential for optimal diabetes care. Here, we estimated the prevalence and determinants of CVD risk factor control among individuals with diagnosed diabetes in Mexico. Methods: We analyzed data from individuals ≥20 years with diagnosed diabetes from 2016 to 2023 Mexican National Health and Nutrition Surveys. We estimated the prevalence of glycemic, blood pressure, noncurrent smoking, low‐density lipoprotein cholesterol, and combined CVD risk factor control. We estimated use of blood pressure‐lowering, cholesterol‐lowering, and glucose‐lowering medication and explored determinants of control achievement using logistic regression. Results: We analyzed data from 2916 participants, representing 43.2 million adults with diagnosed diabetes during 2016 to 2023. In 2023, glycemic control was 29% (95% CI, 21%–38%), blood pressure control 22.9% (95% CI, 14%–31%), and noncurrent smoking 89% (95% CI, 81%–96%). The prevalence of high or very‐high CVD risk using Systematic Coronary Risk Evaluation 2‐Diabetes increased from 59.8% (95% CI, 52.1%–67.0%) in 2016 to 68.4% (95% CI, 55.6%–78.9%) in 2023, representing ~5.1 million adults. Low‐density lipoprotein cholesterol control increased from 2.8% (95% CI, 1.2%–4.4%) in 2016 to 6.6% (95% CI, 1.9%–11.2%) in 2023 and statin use from 5.5% in 2016 to 63% in 2023. Combined risk factor control achievement was low due to suboptimal low‐density lipoprotein cholesterol control and was more likely achieved in women, younger individuals, and those with college education or living in states with higher socioeconomic position. Conclusions: Despite increasing CVD risk during this period, glycemic and CVD risk factor management for adults with diabetes in Mexico remains suboptimal. Our findings suggest a need for strategies to improve CVD risk management to reduce diabetes‐related mortality and complications.
- Open Access
- 23 September 2025
- Published by Servicio de Publicaciones de la Universidad de Murcia in Revista Española de Educación Médica
- Vol. 6 (5)
¿Cómo se comunican los estudiantes de medicina? Un abordaje de los perfiles de comunicación en estudiantes del tercer año de medicina.
Introduction: Effective communication assessment during clinical clerkships has been prioritized by medical schools. Consequently, we developed a rubric to assess the communication profile based on the physician-patient relationship, examined communication profiles and promoted self-directed learning strategies. Objective: To explore the predominant profile of third-year medical students and to foster the development of self-directed learning. Methods: We conducted an exploratory mixed-methods study using data from the Academic Advance Assessment II delivered to third year medical students, based on constructed-response items. We included four items designed to assess effective communication. A category tree was developed based on physician-patient communication styles and models. Correspondence analysis was performed to examine the association between response style categories, expert classifications, and the scores obtained. Results: We identified three profiles among the students: disease-centred profile (DCP) [n=152, 66.7%], dissonant profile (DP) [n=40, 17.5%], and patient-centred profile (PCP) [n=36, 15.8%]. We found that PCP was associated with excellent/sufficient performance levels based on the rubrics, while DP was associated with deficient/insufficient levels. Therefore, the items that assessed effective communication competency, demonstrated an association with the communication profiles identified. Conclusions: Most medical students exhibited a DCP, highlighting the need to strengthen their patient-centred communication skills. Moreover, we identified that there is a lack of focus on effective communication, the urgent need to implement adequate assessment strategies and provide feedback to students on communication skills. Introducción: La evaluación de la comunicación efectiva durante las rotaciones clínicas ha sido priorizada por las escuelas de medicina. Se construyó una rúbrica para evaluar perfiles de comunicación basados en la relación médico-paciente, se examinaron estos perfiles y sugirieron estrategias de autoaprendizaje. Objetivo: Explorar los perfiles de comunicación predominantes en el estudiantado de tercer año de la LMC y fomentar estrategias de aprendizaje autorregulado. Métodos: Se diseñó un estudio exploratorio de métodos mixtos para analizar los datos obtenidos de la Evaluación de Avance Académico II, diseñado con ítems de respuesta construida, aplicado a estudiantes de medicina del tercer año. Se diseñaron cuatro ítems para evaluar la comunicación efectiva y un árbol de categorías basados en los estilos de comunicación médico-paciente. Se realizó un análisis de correspondencia para evaluar la asociación entre las categorías de estilo de las respuestas, clasificaciones de expertos y puntajes obtenidos. Resultados: Se identificaron tres perfiles: perfil centrado en la enfermedad (PCE) [n=152, 66.7%], perfil disonante (PD) [n=40, 17.5%] y perfil centrado en el paciente (PCP) [n=36, 15.8%]. El PCP estuvo asociado con el nivel de desempeño excelente/suficiente, mientras que el PD estuvo asociado con el nivel deficiente/insuficiente. Los ítems que evaluaron la competencia de comunicación efectiva demostraron tener una asociación con los perfiles de comunicación identificados. Conclusiones: La mayoría de los estudiantes de medicina se clasificaron con PCE, indicando que se deben reforzar sus habilidades de comunicación centradas en el paciente. Se identificó que existe una falta de enfoque hacia la comunicación efectiva; así como, la urgencia de implementar estrategias de evaluación adecuadas y realimentación a los estudiantes acerca de las habilidades de comunicación.
- 23 September 2025
- Published by Servicio de Publicaciones de la Universidad de Murcia in Revista Española de Educación Médica
- Vol. 6 (5)
Open Access¿Cómo se comunican los estudiantes de medicina? Un abordaje de los perfiles de comunicación en estudiantes del tercer año de medicina.
Introduction: Effective communication assessment during clinical clerkships has been prioritized by medical schools. Consequently, we developed a rubric to assess the communication profile based on the physician-patient relationship, examined communication profiles and promoted self-directed learning strategies. Objective: To explore the predominant profile of third-year medical students and to foster the development of self-directed learning. Methods: We conducted an exploratory mixed-methods study using data from the Academic Advance Assessment II delivered to third year medical students, based on constructed-response items. We included four items designed to assess effective communication. A category tree was developed based on physician-patient communication styles and models. Correspondence analysis was performed to examine the association between response style categories, expert classifications, and the scores obtained. Results: We identified three profiles among the students: disease-centred profile (DCP) [n=152, 66.7%], dissonant profile (DP) [n=40, 17.5%], and patient-centred profile (PCP) [n=36, 15.8%]. We found that PCP was associated with excellent/sufficient performance levels based on the rubrics, while DP was associated with deficient/insufficient levels. Therefore, the items that assessed effective communication competency, demonstrated an association with the communication profiles identified. Conclusions: Most medical students exhibited a DCP, highlighting the need to strengthen their patient-centred communication skills. Moreover, we identified that there is a lack of focus on effective communication, the urgent need to implement adequate assessment strategies and provide feedback to students on communication skills. Introducción: La evaluación de la comunicación efectiva durante las rotaciones clínicas ha sido priorizada por las escuelas de medicina. Se construyó una rúbrica para evaluar perfiles de comunicación basados en la relación médico-paciente, se examinaron estos perfiles y sugirieron estrategias de autoaprendizaje. Objetivo: Explorar los perfiles de comunicación predominantes en el estudiantado de tercer año de la LMC y fomentar estrategias de aprendizaje autorregulado. Métodos: Se diseñó un estudio exploratorio de métodos mixtos para analizar los datos obtenidos de la Evaluación de Avance Académico II, diseñado con ítems de respuesta construida, aplicado a estudiantes de medicina del tercer año. Se diseñaron cuatro ítems para evaluar la comunicación efectiva y un árbol de categorías basados en los estilos de comunicación médico-paciente. Se realizó un análisis de correspondencia para evaluar la asociación entre las categorías de estilo de las respuestas, clasificaciones de expertos y puntajes obtenidos. Resultados: Se identificaron tres perfiles: perfil centrado en la enfermedad (PCE) [n=152, 66.7%], perfil disonante (PD) [n=40, 17.5%] y perfil centrado en el paciente (PCP) [n=36, 15.8%]. El PCP estuvo asociado con el nivel de desempeño excelente/suficiente, mientras que el PD estuvo asociado con el nivel deficiente/insuficiente. Los ítems que evaluaron la competencia de comunicación efectiva demostraron tener una asociación con los perfiles de comunicación identificados. Conclusiones: La mayoría de los estudiantes de medicina se clasificaron con PCE, indicando que se deben reforzar sus habilidades de comunicación centradas en el paciente. Se identificó que existe una falta de enfoque hacia la comunicación efectiva; así como, la urgencia de implementar estrategias de evaluación adecuadas y realimentación a los estudiantes acerca de las habilidades de comunicación.
- Open Access
Evolving patterns of prevalence and management of hypertension phenotypes in Mexico: A two-decade analysis of nationally representative surveys
BACKGROUND: Systemic arterial hypertension is a public health concern, and timely diagnosis and management are critical to mitigate long-term effects. Here, we evaluated prevalence trends and determinants of hypertension and its phenotypes in Mexican population over the last two decades. METHODS: We analyzed cross-sectional Mexican Health and Nutrition Surveys (2000-2023), including 141,668 adults aged ≥20 years. Hypertension was defined as self-reported diagnosis or blood pressure (BP) ≥140/90 mmHg; undiagnosed hypertension (UDH) as BP ≥140/90 mmHg without prior diagnosis; and untreated hypertension (UTH) as prior diagnosis without treatment. UDH was classified as isolated systolic (ISH), isolated diastolic (IDH), or systolic-diastolic hypertension (SDH). We assessed prevalence trends with Poisson models, and determinants of UDH and UTH with logistic models. RESULTS: We observed an overall decrease in hypertension prevalence from 2000 to 2023, driven by increases in diagnosed (12.3% to 19.3%) and decreases in undiagnosed (20.7% to 11%) hypertension. IDH and SDH declined over time, while ISH increased, particularly among older adults. Among diagnosed cases, UTH decreased (31% to 19.5%) and BP control improved (40.5% to 69.5%). Despite these trends, by 2023 approximately 8.2 million Mexican adults still had UDH (36.3% of all hypertension cases), 2.8 million remained untreated, and 4.4 million uncontrolled. Lack of diagnosis and treatment were more likely among men, individuals with unhealthy lifestyles, and social disadvantage. CONCLUSIONS: Results highlight evolving trends in hypertension diagnosis, treatment, and control in Mexico, with persistent challenges in UDH and UTH. Strengthening screening, treatment access, and equity is crucial to reduce hypertension-related cardiovascular risk.
Open AccessEvolving patterns of prevalence and management of hypertension phenotypes in Mexico: A two-decade analysis of nationally representative surveys
BACKGROUND: Systemic arterial hypertension is a public health concern, and timely diagnosis and management are critical to mitigate long-term effects. Here, we evaluated prevalence trends and determinants of hypertension and its phenotypes in Mexican population over the last two decades. METHODS: We analyzed cross-sectional Mexican Health and Nutrition Surveys (2000-2023), including 141,668 adults aged ≥20 years. Hypertension was defined as self-reported diagnosis or blood pressure (BP) ≥140/90 mmHg; undiagnosed hypertension (UDH) as BP ≥140/90 mmHg without prior diagnosis; and untreated hypertension (UTH) as prior diagnosis without treatment. UDH was classified as isolated systolic (ISH), isolated diastolic (IDH), or systolic-diastolic hypertension (SDH). We assessed prevalence trends with Poisson models, and determinants of UDH and UTH with logistic models. RESULTS: We observed an overall decrease in hypertension prevalence from 2000 to 2023, driven by increases in diagnosed (12.3% to 19.3%) and decreases in undiagnosed (20.7% to 11%) hypertension. IDH and SDH declined over time, while ISH increased, particularly among older adults. Among diagnosed cases, UTH decreased (31% to 19.5%) and BP control improved (40.5% to 69.5%). Despite these trends, by 2023 approximately 8.2 million Mexican adults still had UDH (36.3% of all hypertension cases), 2.8 million remained untreated, and 4.4 million uncontrolled. Lack of diagnosis and treatment were more likely among men, individuals with unhealthy lifestyles, and social disadvantage. CONCLUSIONS: Results highlight evolving trends in hypertension diagnosis, treatment, and control in Mexico, with persistent challenges in UDH and UTH. Strengthening screening, treatment access, and equity is crucial to reduce hypertension-related cardiovascular risk.
- Open Access
- 26 May 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-12
Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk.
- 26 May 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-12
Open AccessLipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk.
- Open Access
- 10 April 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , 3451-3460
Prediabetes and Risk of All-Cause and Cause-Specific Mortality: A Prospective Study of 114 062 Adults in Mexico City
Background: Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations. Methods: We analyzed data from 114 062 adults without diabetes (diagnosed or undiagnosed) from the Mexico City Prospective Study. Participants were followed until January 1, 2021, for cause-specific mortality. We defined prediabetes according to the American Diabetes Association (ADA; HbA1c ≥ 5.7% to <6.5%) and the International Expert Committee (IEC; HbA1c ≥ 6.0 to <6.5%) definitions. Cox regression adjusted for confounders was used to estimate all-cause and cause-specific mortality rate ratios (RR) for deaths occurring at ages 35 to 74 years associated with prediabetes. Results: After median 18.4 (IQR 17.6-19.7) years of follow-up, individuals with prediabetes had higher risk of all-cause mortality at ages 35 to 74 compared to those without prediabetes (RR 1.13 [1.07-1.20] for ADA-defined and 1.27 [1.17-1.38] for IEC-defined prediabetes), as well as higher risk of cardiovascular (RR 1.23 [1.11-1.37] and 1.44 [1.24-1.67], respectively), renal (RR 1.33 [1.06-1.66] and 1.62 [1.18-2.23], respectively), and acute diabetic deaths (RR 2.62 [1.75-3.93] and 3.42 [2.09-5.61], respectively). The absolute excess risk associated with ADA-defined prediabetes at ages 35 to 74 accounted for 7% of cardiovascular, 9% of renal, and 31% of acute diabetic deaths. IEC-defined prediabetes accounted for 4%, 5% and 14% of cardiovascular, renal, and acute diabetic deaths. Prediabetes-associated excess mortality risks were, at least in part, explained by adiposity. Conclusion: Prediabetes is a significant risk factor for all-cause, cardiovascular, renal, and acute diabetic deaths in Mexican adults. Early identification and timely management of prediabetes among individuals at risk of this condition could reduce premature mortality in this population.
- 10 April 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (12) , 3451-3460
Open AccessPrediabetes and Risk of All-Cause and Cause-Specific Mortality: A Prospective Study of 114 062 Adults in Mexico City
Background: Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations. Methods: We analyzed data from 114 062 adults without diabetes (diagnosed or undiagnosed) from the Mexico City Prospective Study. Participants were followed until January 1, 2021, for cause-specific mortality. We defined prediabetes according to the American Diabetes Association (ADA; HbA1c ≥ 5.7% to <6.5%) and the International Expert Committee (IEC; HbA1c ≥ 6.0 to <6.5%) definitions. Cox regression adjusted for confounders was used to estimate all-cause and cause-specific mortality rate ratios (RR) for deaths occurring at ages 35 to 74 years associated with prediabetes. Results: After median 18.4 (IQR 17.6-19.7) years of follow-up, individuals with prediabetes had higher risk of all-cause mortality at ages 35 to 74 compared to those without prediabetes (RR 1.13 [1.07-1.20] for ADA-defined and 1.27 [1.17-1.38] for IEC-defined prediabetes), as well as higher risk of cardiovascular (RR 1.23 [1.11-1.37] and 1.44 [1.24-1.67], respectively), renal (RR 1.33 [1.06-1.66] and 1.62 [1.18-2.23], respectively), and acute diabetic deaths (RR 2.62 [1.75-3.93] and 3.42 [2.09-5.61], respectively). The absolute excess risk associated with ADA-defined prediabetes at ages 35 to 74 accounted for 7% of cardiovascular, 9% of renal, and 31% of acute diabetic deaths. IEC-defined prediabetes accounted for 4%, 5% and 14% of cardiovascular, renal, and acute diabetic deaths. Prediabetes-associated excess mortality risks were, at least in part, explained by adiposity. Conclusion: Prediabetes is a significant risk factor for all-cause, cardiovascular, renal, and acute diabetic deaths in Mexican adults. Early identification and timely management of prediabetes among individuals at risk of this condition could reduce premature mortality in this population.
- Open Access
Cardiovascular risk management in adults with diagnosed diabetes in Mexico from 2016–2023: A retrospective analysis of nationally representative surveys
BACKGROUND Cardiovascular (CVD) risk factor reduction is a cornerstone of diabetes management. Here, we aimed to estimate the prevalence and determinants of individual and combined CVD risk factor control goals amongst individuals living with diagnosed diabetes in Mexico. METHODS We analyzed Mexican National Health and Nutrition Surveys from 2016-2022 including individuals aged ≥20 years with diagnosed diabetes. We estimated the prevalence of glycemic, blood pressure, cholesterol, and smoking control, as well as combined control achievement according to current guidelines, as well as the prevalence of antihypertensive, statin and diabetes medication use. We also explored determinants of control achievement amongst individuals with diabetes using weighted logistic regression. RESULTS We analyzed data from 2,331 adults with diagnosed diabetes. Glycemic control increased over time reaching 41% (95%CI 30%–52%) by 2022. Blood pressure control remained similar over time reaching 45% (95%CI 35%–55%) in 2022, LDL-C control remained low regardless of the definition (CONCLUSIONS Our results suggest a need to improve comprehensive glycemic and CVD risk factor management for individuals living with diabetes in Mexico to improve diabetes care and reduce risk of adverse outcomes.
Open AccessCardiovascular risk management in adults with diagnosed diabetes in Mexico from 2016–2023: A retrospective analysis of nationally representative surveys
BACKGROUND Cardiovascular (CVD) risk factor reduction is a cornerstone of diabetes management. Here, we aimed to estimate the prevalence and determinants of individual and combined CVD risk factor control goals amongst individuals living with diagnosed diabetes in Mexico. METHODS We analyzed Mexican National Health and Nutrition Surveys from 2016-2022 including individuals aged ≥20 years with diagnosed diabetes. We estimated the prevalence of glycemic, blood pressure, cholesterol, and smoking control, as well as combined control achievement according to current guidelines, as well as the prevalence of antihypertensive, statin and diabetes medication use. We also explored determinants of control achievement amongst individuals with diabetes using weighted logistic regression. RESULTS We analyzed data from 2,331 adults with diagnosed diabetes. Glycemic control increased over time reaching 41% (95%CI 30%–52%) by 2022. Blood pressure control remained similar over time reaching 45% (95%CI 35%–55%) in 2022, LDL-C control remained low regardless of the definition (CONCLUSIONS Our results suggest a need to improve comprehensive glycemic and CVD risk factor management for individuals living with diabetes in Mexico to improve diabetes care and reduce risk of adverse outcomes.
- Open Access
Smoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico City Prospective Study
BACKGROUND: Evidence from low– and middle-income countries regarding the effect of smoking in people with diabetes is lacking. Here, we report the association of smoking with mortality in a large cohort of Mexican adults with diabetes. METHODS: Participants with diabetes mellitus (self-reported medical diagnosis, use of antidiabetic medications or HbA1c ≥6.5%) aged 35-74 years when recruited into the Mexico City Prospective Study were included. Cox regression confounder-adjusted mortality rate ratios (RRs) associated with baseline smoking status were estimated. FINDINGS: Among 15,975 women and 8225 men aged 35-74 years with diabetes but no other comorbidities at recruitment, 2498 (16%) women and 2875 (35%) men reported former smoking and 2753 (17%) women, and 3796 (46%) men reported current smoking. Smoking less than daily was common: 39.4% of female current smokers and 30.7% of male current smokers. During a median of 17 years of follow-up there were 5087 deaths at ages 35-74 years. Compared with never smoking, the all-cause mortality RR was 1.08 (95%CI 1.01–1.17) for former smoking, 1.09 (95%CI 0.99–1.20) for non-daily smoking, 1.06 (95%CI 0.96–1.16) for smoking st , 2023, using the terms ((diabetes mellitus) OR (type 2 diabetes mellitus)) AND ((smoking) OR (tobacco)) AND ((mortality) OR (survival analysis) OR (death)). We identified a meta-analysis published in 2015 which analysed data from 1,132,700 participants with diabetes from 89 cohort studies. Among current and former smokers, the pooled adjusted relative risk for all-cause mortality was 1.55 (95% CI 1.46–1.64) and 1.19 (95% CI 1.11–1.28), respectively. Among current smokers, there was considerably higher risk of death due to cardiovascular disease, coronary heart disease, stroke, peripheral arterial disease, and heart failure. Most included studies were conducted in high income countries and only one was done in Latin America (Argentina, 1,730 participants). In Mexico, epidemiological studies related to smoking have been primarily descriptive in nature. A previous study of the MCPS that analysed all-cause smoking-related mortality among disease-free individuals found adjusted rate ratios among daily smokers of 1.17 (95% CI 1.10–1.25) for those using <10 cigarettes/day and 1.54 (95% CI 1.42–1.67) for those using ≥10 cigarettes/day. In this study, mortality risk in people with diabetes was not assessed separately. Instead, mortality risk estimates were obtained for several chronic diseases as a group. No other studies have analysed changes in smoking habits and smoking-related mortality in Mexican individuals with diabetes. Added value of this study: To our knowledge, this is the first analysis of longitudinal data of Mexican adults with diabetes (n=24,200) followed over 17 years, to examine the association between smoking and all-cause and cause-specific mortality. Compared with never smokers with diabetes, former and daily smokers with diabetes had elevated mortality. Among daily smokers there was higher risk of death due to cardiovascular disease, acute diabetes complications, lung cancer and COPD. Our results are generally consistent with previous analyses that have found smoking as a significant risk factor for higher mortality in individuals with diabetes. Our estimates, however, are comparably lower for all-cause mortality, possibly related to distinct smoking habits specific to the Mexican population with diabetes. Implications of all available evidence: Our results confirm that smoking is a significant risk factor for all-cause and cause-specific mortality among Mexican adults with diabetes. Strategies to promote smoking cessation among individuals with diabetes should be encouraged, particularly given that tobacco use is a modifiable risk factor. This is especially meaningful in middle-to lower-income countries like Mexico, where diabetes prevalence is increasing and achieving glycaemic targets remains a challenge.
Open AccessSmoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico City Prospective Study
BACKGROUND: Evidence from low– and middle-income countries regarding the effect of smoking in people with diabetes is lacking. Here, we report the association of smoking with mortality in a large cohort of Mexican adults with diabetes. METHODS: Participants with diabetes mellitus (self-reported medical diagnosis, use of antidiabetic medications or HbA1c ≥6.5%) aged 35-74 years when recruited into the Mexico City Prospective Study were included. Cox regression confounder-adjusted mortality rate ratios (RRs) associated with baseline smoking status were estimated. FINDINGS: Among 15,975 women and 8225 men aged 35-74 years with diabetes but no other comorbidities at recruitment, 2498 (16%) women and 2875 (35%) men reported former smoking and 2753 (17%) women, and 3796 (46%) men reported current smoking. Smoking less than daily was common: 39.4% of female current smokers and 30.7% of male current smokers. During a median of 17 years of follow-up there were 5087 deaths at ages 35-74 years. Compared with never smoking, the all-cause mortality RR was 1.08 (95%CI 1.01–1.17) for former smoking, 1.09 (95%CI 0.99–1.20) for non-daily smoking, 1.06 (95%CI 0.96–1.16) for smoking st , 2023, using the terms ((diabetes mellitus) OR (type 2 diabetes mellitus)) AND ((smoking) OR (tobacco)) AND ((mortality) OR (survival analysis) OR (death)). We identified a meta-analysis published in 2015 which analysed data from 1,132,700 participants with diabetes from 89 cohort studies. Among current and former smokers, the pooled adjusted relative risk for all-cause mortality was 1.55 (95% CI 1.46–1.64) and 1.19 (95% CI 1.11–1.28), respectively. Among current smokers, there was considerably higher risk of death due to cardiovascular disease, coronary heart disease, stroke, peripheral arterial disease, and heart failure. Most included studies were conducted in high income countries and only one was done in Latin America (Argentina, 1,730 participants). In Mexico, epidemiological studies related to smoking have been primarily descriptive in nature. A previous study of the MCPS that analysed all-cause smoking-related mortality among disease-free individuals found adjusted rate ratios among daily smokers of 1.17 (95% CI 1.10–1.25) for those using <10 cigarettes/day and 1.54 (95% CI 1.42–1.67) for those using ≥10 cigarettes/day. In this study, mortality risk in people with diabetes was not assessed separately. Instead, mortality risk estimates were obtained for several chronic diseases as a group. No other studies have analysed changes in smoking habits and smoking-related mortality in Mexican individuals with diabetes. Added value of this study: To our knowledge, this is the first analysis of longitudinal data of Mexican adults with diabetes (n=24,200) followed over 17 years, to examine the association between smoking and all-cause and cause-specific mortality. Compared with never smokers with diabetes, former and daily smokers with diabetes had elevated mortality. Among daily smokers there was higher risk of death due to cardiovascular disease, acute diabetes complications, lung cancer and COPD. Our results are generally consistent with previous analyses that have found smoking as a significant risk factor for higher mortality in individuals with diabetes. Our estimates, however, are comparably lower for all-cause mortality, possibly related to distinct smoking habits specific to the Mexican population with diabetes. Implications of all available evidence: Our results confirm that smoking is a significant risk factor for all-cause and cause-specific mortality among Mexican adults with diabetes. Strategies to promote smoking cessation among individuals with diabetes should be encouraged, particularly given that tobacco use is a modifiable risk factor. This is especially meaningful in middle-to lower-income countries like Mexico, where diabetes prevalence is increasing and achieving glycaemic targets remains a challenge.
- Open Access
Nationally representative prevalence and determinants of post-acute sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in 2022
OBJECTIVE: To characterize the epidemiology of post-acute sequelae after SARS-CoV-2 infection (PASC) in Mexico during 2022 and identify potential predictors of PASC prevalence using nationally representative data. METHODS: We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) totaling 24,434 participants, representing 85,521,661 adults ≥20 years. PASC was defined using both the World Health Organization definition and a PASC score ≥12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and by periods of predominance of SARS-CoV-2 circulating variants. Predictors of PASC were assessed using logistic regression models adjusted by survey weights. RESULTS: Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95%CI 11.89-12.99) of adults ≥20 years in Mexico during 2022. The most common persistent symptoms were musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. PASC was present in 21.21% (95%CI 7.71-9.65) subjects with previously diagnosed COVID-19. Over 28.6% patients with PASC reported symptoms persistence ≥6 months and 14.05% reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and for infections during periods of Omicron variant predominance. CONCLUSIONS: PASC implies a significant public health burden in Mexico as the COVID-19 pandemic transitions into endemicity. Promoting reinfection prevention and booster vaccination may be useful to reduce PASC burden.
Open AccessNationally representative prevalence and determinants of post-acute sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in 2022
OBJECTIVE: To characterize the epidemiology of post-acute sequelae after SARS-CoV-2 infection (PASC) in Mexico during 2022 and identify potential predictors of PASC prevalence using nationally representative data. METHODS: We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) totaling 24,434 participants, representing 85,521,661 adults ≥20 years. PASC was defined using both the World Health Organization definition and a PASC score ≥12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and by periods of predominance of SARS-CoV-2 circulating variants. Predictors of PASC were assessed using logistic regression models adjusted by survey weights. RESULTS: Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95%CI 11.89-12.99) of adults ≥20 years in Mexico during 2022. The most common persistent symptoms were musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, chest pain, and sleep disorders. PASC was present in 21.21% (95%CI 7.71-9.65) subjects with previously diagnosed COVID-19. Over 28.6% patients with PASC reported symptoms persistence ≥6 months and 14.05% reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and for infections during periods of Omicron variant predominance. CONCLUSIONS: PASC implies a significant public health burden in Mexico as the COVID-19 pandemic transitions into endemicity. Promoting reinfection prevention and booster vaccination may be useful to reduce PASC burden.
- Open Access
Prevalence of untreated prediabetes and glucose metabolism disturbances in Mexico: An analysis of nationally representative surveys spanning 2016-2021
OBJECTIVE Characterizing prediabetes phenotypes may be useful in guiding diabetes prevention efforts; however, heterogeneous criteria to define prediabetes have led to inconsistent prevalence estimates, particularly in low- and middle-income countries. We estimated trends in untreated prediabetes prevalence in Mexico across different definitions and its association with prevalent cardiometabolic conditions. METHODS We conducted a serial cross-sectional analysis of National Health and Nutrition Surveys in Mexico (2016-2021), totaling 21,442 Mexican adults, excluding individuals with diagnosed or undiagnosed diabetes. Prediabetes was defined using ADA (impaired fasting glucose [IFG] 100-125 mg/dL and/or HbA1c 5.7-6.4%), WHO (IFG 110-125 mg/dL), and IEC criteria (HbA1c 6.0-6.4%). Prevalence trends of prediabetes over time were evaluated using Poisson regression and its association with prevalent cardiometabolic conditions with logistic regression. RESULTS Prevalence of prediabetes in Mexico in 2021 was 27.3%. Despite an overall downward trend in prediabetes (RR 0.960, 95%CI 0.940-0.979), this decrease was primarily driven by decreases in prediabetes by ADA-IFG (RR 0.883, 95%CI 0.861-0.907) and WHO-IFG criteria (RR 0.878, 95%CI 0.838-0.921), while prediabetes by ADA-HbA1c (RR 1.049, 95%CI 1.022-1.077) and IEC-HbA1C criteria (RR 1.064, 95%CI 1.014-1.115) increased over time. Prediabetes prevalence increased over time in adults >40 years, individuals with central obesity, self-identified as indigenous or living in urban areas. Regardless of the definition, prediabetes was associated with increased risk of cardiometabolic conditions. CONCLUSIONS Prediabetes rates in Mexico from 2016-2021 varied based on defining criteria but consistently increased for HbA1c-based definitions and high-risk subgroups. Regardless of the definition, prediabetes clusters subjects with high cardiometabolic risk.
Open AccessPrevalence of untreated prediabetes and glucose metabolism disturbances in Mexico: An analysis of nationally representative surveys spanning 2016-2021
OBJECTIVE Characterizing prediabetes phenotypes may be useful in guiding diabetes prevention efforts; however, heterogeneous criteria to define prediabetes have led to inconsistent prevalence estimates, particularly in low- and middle-income countries. We estimated trends in untreated prediabetes prevalence in Mexico across different definitions and its association with prevalent cardiometabolic conditions. METHODS We conducted a serial cross-sectional analysis of National Health and Nutrition Surveys in Mexico (2016-2021), totaling 21,442 Mexican adults, excluding individuals with diagnosed or undiagnosed diabetes. Prediabetes was defined using ADA (impaired fasting glucose [IFG] 100-125 mg/dL and/or HbA1c 5.7-6.4%), WHO (IFG 110-125 mg/dL), and IEC criteria (HbA1c 6.0-6.4%). Prevalence trends of prediabetes over time were evaluated using Poisson regression and its association with prevalent cardiometabolic conditions with logistic regression. RESULTS Prevalence of prediabetes in Mexico in 2021 was 27.3%. Despite an overall downward trend in prediabetes (RR 0.960, 95%CI 0.940-0.979), this decrease was primarily driven by decreases in prediabetes by ADA-IFG (RR 0.883, 95%CI 0.861-0.907) and WHO-IFG criteria (RR 0.878, 95%CI 0.838-0.921), while prediabetes by ADA-HbA1c (RR 1.049, 95%CI 1.022-1.077) and IEC-HbA1C criteria (RR 1.064, 95%CI 1.014-1.115) increased over time. Prediabetes prevalence increased over time in adults >40 years, individuals with central obesity, self-identified as indigenous or living in urban areas. Regardless of the definition, prediabetes was associated with increased risk of cardiometabolic conditions. CONCLUSIONS Prediabetes rates in Mexico from 2016-2021 varied based on defining criteria but consistently increased for HbA1c-based definitions and high-risk subgroups. Regardless of the definition, prediabetes clusters subjects with high cardiometabolic risk.